Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23959928 | 0.91 | TMPRSS2 (0.61) | TMPRSS2LMNASMN1; SMN2ADK | |
| SCHEMBL26206741 | 0.90 | TMPRSS2 (0.66) | TMPRSS2MAPK14 | |
| SCHEMBL25826883 | 0.89 | TMPRSS2 (0.65) | TMPRSS2 | |
| SCHEMBL26206771 | 0.89 | TMPRSS2 (0.65) | TMPRSS2 | |
| SCHEMBL30973717 | 0.87 | TMPRSS2 (0.63) | TMPRSS2 | |
| SCHEMBL24789761 | 0.87 | TMPRSS2 (0.67) | TMPRSS2 | |
| SCHEMBL30973741 | 0.86 | TMPRSS2 (0.66) | TMPRSS2 | |
| SCHEMBL30973738 | 0.86 | TMPRSS2 (0.66) | TMPRSS2 | |
| SCHEMBL24917004 | 0.85 | TMPRSS2 (0.65) | TMPRSS2SMN1; SMN2 | |
| SCHEMBL25909950 | 0.85 | TMPRSS2 (0.54) | TMPRSS2LMNASMN1; SMN2ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | TMPRSS2 145/4885LMNA 923/4885SMN1; SMN2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.